#  The Efficacy of mRNA Vaccine Technology Against Emerging Viral Variants

Okay, here is a research paper formatted according to your specifications, addressing the efficacy of mRNA vaccine technology against emerging viral variants.

**Please Note:** This paper synthesizes information broadly available up to early 2024. The field is rapidly evolving, and specific data points (like efficacy percentages) change with new studies and variants. The references are illustrative examples in APA format; a real research paper would require specific, up-to-date citations based on a comprehensive literature search.

---

**1. Title Page**

**The Efficacy of mRNA Vaccine Technology Against Emerging Viral Variants: A Comprehensive Review**

[Your Name/Author Placeholder]
[Your Affiliation/Institutional Placeholder]
[Date: Month Day, Year - e.g., October 26, 2023]

---

**2. Abstract**

The emergence of novel viral pathogens, exemplified by SARS-CoV-2, underscores the critical need for adaptable vaccine platforms. Messenger RNA (mRNA) vaccine technology has revolutionized vaccinology, offering unprecedented speed in development and deployment. This review synthesizes current evidence on the efficacy of mRNA vaccines (primarily BNT162b2/Pfizer-BioNTech and mRNA-1273/Moderna) against emerging variants of SARS-CoV-2, the most prominent recent example. Initial clinical trials demonstrated remarkable efficacy (>90%) against the ancestral strain. However, subsequent viral evolution, leading to variants of concern (VOCs) like Alpha, Beta, Delta, and particularly Omicron and its sublineages, presented challenges due to mutations in the spike protein, the primary vaccine target. Studies indicate a decline in vaccine effectiveness (VE) against infection and symptomatic disease caused by variants, especially Omicron, although protection against severe disease, hospitalization, and death remains more robust, particularly after booster doses. This sustained protection is likely mediated by a combination of residual neutralizing antibodies and durable T-cell responses, which appear less susceptible to spike mutations. The flexibility of mRNA technology has enabled rapid development of updated, variant-adapted (e.g., bivalent) boosters, partially restoring neutralizing antibody titers and enhancing protection. Ongoing surveillance, continued research into correlates of protection beyond neutralization, and strategic booster campaigns remain crucial for mitigating the impact of future viral variants.

*(Word Count: approx. 198)*

---

**3. Introduction**

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlighted the profound global impact of emerging infectious diseases and catalyzed vaccine development at an unparalleled pace (Krammer, 2020). Among the leading technologies deployed were messenger RNA (mRNA) vaccines. Unlike traditional vaccines that introduce inactivated viruses or viral proteins, mRNA vaccines utilize lipid nanoparticles (LNPs) to deliver mRNA encoding a specific viral antigen – in the case of SARS-CoV-2, the spike (S) protein – directly into host cells (Pardi et al., 2018). Host cellular machinery then translates this mRNA, producing the viral protein, which triggers a robust humoral (antibody) and cellular (T-cell) immune response, mimicking natural infection without causing disease (Sahin et al., 2020).

The key advantages of mRNA technology include its potential for rapid design, scalability, and manufacturing speed, making it exceptionally well-suited for pandemic response scenarios (Jackson et al., 2020). Initial phase 3 clinical trials for the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines reported outstanding efficacy rates exceeding 90% against symptomatic infection caused by the ancestral SARS-CoV-2 strain (Polack et al., 2020; Baden et al., 2021).

However, RNA viruses, including coronaviruses, inherently possess high mutation rates. Continuous viral replication, particularly during widespread transmission, coupled with selective pressures (including population immunity from infection or vaccination), drives viral evolution, leading to the emergence of variants (Lauring & Hodcroft, 2021). Some variants acquire mutations that enhance transmissibility, virulence, or enable immune evasion, potentially compromising the effectiveness of existing diagnostics, therapeutics, and vaccines. Variants of Concern (VOCs) such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and subsequently the highly mutated Omicron (B.1.1.529) and its numerous sublineages (BA.1, BA.2, BA.4/5, XBB, etc.), have posed significant challenges to global public health efforts (Harvey et al., 2021; Planas et al., 2022).

Understanding the extent to which mRNA vaccines maintain efficacy against these evolving viral threats is critical for informing public health strategies, including vaccination schedules, booster recommendations, and the development of next-generation vaccines. This review aims to comprehensively evaluate the efficacy of mRNA vaccine technology against emerging SARS-CoV-2 variants by synthesizing findings from clinical trials, real-world effectiveness studies, and immunological assays. It will examine the impact of variants on vaccine-induced immunity, the role of booster doses, the contribution of T-cell immunity, and the adaptability of the mRNA platform itself.

---

**4. Methodology**

This research paper employs a comprehensive literature review methodology to synthesize and evaluate existing evidence on the efficacy of mRNA vaccines against emerging viral variants, primarily focusing on SARS-CoV-2.

**Search Strategy:** A systematic search of electronic databases, including PubMed/MEDLINE, Scopus, Google Scholar, and preprint servers (medRxiv, bioRxiv), was conducted. Search terms included combinations of: "mRNA vaccine," "BNT162b2," "mRNA-1273," "SARS-CoV-2," "COVID-19," "variants of concern," "VOC," "Alpha," "Beta," "Gamma," "Delta," "Omicron," "sublineages," "efficacy," "effectiveness," "neutralizing antibodies," "T-cell response," "immune escape," "booster dose," and "bivalent vaccine." The search was primarily focused on publications from December 2020 through early 2024. Reference lists of relevant reviews and retrieved articles were also manually screened for additional pertinent studies.

**Inclusion and Exclusion Criteria:** Studies were included if they were peer-reviewed original research articles (clinical trials, observational cohort studies, case-control studies, immunological laboratory studies), systematic reviews, meta-analyses, or authoritative public health reports (e.g., from WHO, CDC, ECDC). Studies had to report data specifically on the efficacy or immunogenicity of mRNA vaccines (BNT162b2 or mRNA-1273) against defined SARS-CoV-2 variants. Preprints were considered for very recent data but interpreted with caution. Studies focusing exclusively on non-mRNA vaccines (unless providing direct comparison), animal studies without clear human correlates, opinion pieces, or studies not available in English were generally excluded.

**Data Synthesis and Analysis:** Relevant data regarding vaccine efficacy/effectiveness (VE) against infection, symptomatic disease, hospitalization, and death, as well as immunological data (neutralizing antibody titers, T-cell responses), were extracted from the selected studies. Given the heterogeneity in study designs, populations, variant circulation periods, and outcome definitions, a narrative synthesis approach was adopted rather than a formal meta-analysis of VE percentages. Findings were grouped thematically based on the variant, outcome measured (infection vs. severe disease), primary series vs. booster doses, and type of immune response (humoral vs. cellular). Trends, consistencies, and discrepancies across studies were identified and summarized. The adaptability of the mRNA platform through the development of variant-specific boosters was also assessed based on reported trial and real-world data.

---

**5. Results**

The literature review reveals a dynamic picture of mRNA vaccine efficacy evolving in response to the emergence of new SARS-CoV-2 variants.

**5.1. Efficacy Against Ancestral Strain:** Initial Phase 3 trials demonstrated high efficacy (>90%) of two-dose mRNA vaccine regimens (BNT162b2 and mRNA-1273) against symptomatic COVID-19 caused by the ancestral SARS-CoV-2 strain (Polack et al., 2020; Baden et al., 2021). These vaccines elicited potent neutralizing antibody responses and robust CD4+ and CD8+ T-cell responses.

**5.2. Efficacy Against Early Variants (Alpha, Beta, Gamma, Delta):**
*   **Alpha (B.1.1.7):** Real-world studies and immunological assays generally indicated only a slight reduction in vaccine effectiveness and neutralizing antibody titers against the Alpha variant compared to the ancestral strain (Lopez Bernal et al., 2021). Protection against severe disease remained high.
*   **Beta (B.1.351) & Gamma (P.1):** These variants showed evidence of greater immune evasion, particularly concerning neutralizing antibodies. Laboratory studies demonstrated significant reductions in neutralization titers from vaccinee sera (Wang et al., 2021). Real-world VE against symptomatic infection was lower compared to Alpha, although protection against severe disease largely persisted.
*   **Delta (B.1.617.2):** Delta became globally dominant in mid-2021. While VE against symptomatic infection was moderately reduced compared to the ancestral strain, protection against hospitalization and death remained substantial after two doses (Lopez Bernal et al., 2021; Sheikh et al., 2021). Some waning of protection against infection became apparent several months post-vaccination.

**5.3. Efficacy Against Omicron Sublineages (BA.1, BA.2, BA.4/5, XBB):**
*   The emergence of the Omicron variant (B.1.1.529) in late 2021 marked a significant shift due to its numerous spike mutations. Laboratory studies showed dramatic reductions (20- to 40-fold or more) in neutralization titers against Omicron BA.1 and BA.2 from individuals who had received two doses of an mRNA vaccine (Planas et al., 2022; Cele et al., 2021).
*   Real-world studies confirmed substantial drops in VE against any Omicron infection (symptomatic or asymptomatic), leading to widespread breakthrough infections even among vaccinated individuals (Andrews et al., 2022; Tseng et al., 2022).
*   Critically, protection against severe disease, hospitalization, and death remained considerably higher, although some reduction and evidence of waning were observed compared to Delta (Accorsi et al., 2022). VE against severe outcomes was significantly lower after two doses compared to earlier variants but was substantially restored by booster doses.
*   Subsequent Omicron sublineages (e.g., BA.4/5, BQ.1, XBB) exhibited further immune escape properties relative to BA.1/BA.2, causing further waves of infection (Cao et al., 2022; Wang et al., 2022).

**5.4. Impact of Booster Doses:**
*   A third (booster) dose of the original monovalent mRNA vaccines significantly increased neutralizing antibody titers against both ancestral strains and variants, including Omicron (Garcia-Beltran et al., 2022; Pajon et al., 2022).
*   Booster doses substantially improved VE against symptomatic infection, hospitalization, and death caused by Delta and, importantly, Omicron sublineages, compared to the primary two-dose series, particularly in the initial months following the booster (Andrews et al., 2022; Accorsi et al., 2022).
*   Bivalent boosters, containing mRNA for both the ancestral strain and an Omicron variant (initially BA.1, later BA.4/5), were developed to broaden the immune response. Studies showed that bivalent boosters elicited superior neutralizing antibody responses against targeted Omicron sublineages compared to further monovalent boosters, particularly in individuals with prior infection history (Chalkias et al., 2022; Davis-Gardner et al., 2023). Real-world effectiveness data suggest bivalent boosters provide additional protection against infection and severe outcomes compared to being unvaccinated or having received only monovalent boosters several months prior (Link-Gelles et al., 2023).

**5.5. Role of T-cell Immunity:**
*   Multiple studies indicate that T-cell responses induced by mRNA vaccination are relatively well-preserved against SARS-CoV-2 variants, including Omicron (Keeton et al., 2022; Tarke et al., 2022). This is likely because T-cell epitopes are distributed across the spike protein (and potentially other proteins in infection-induced immunity) and are less affected by the specific point mutations driving antibody evasion in the receptor-binding domain (RBD).
*   This conserved T-cell immunity is hypothesized to play a crucial role in the continued protection against severe disease observed even when neutralizing antibody levels are low or directed against mismatched strains (Gao et al., 2022).

---

**6. Discussion**

The collective evidence demonstrates that mRNA vaccines represent a powerful tool against SARS-CoV-2, but their efficacy is moderated by viral evolution. The initial unparalleled success against the ancestral strain provided crucial protection early in the pandemic. However, the emergence of VOCs, culminating in the highly divergent Omicron lineage, has clearly shown the potential for immune escape, primarily impacting protection against infection and milder symptomatic disease.

The observed pattern – significant reduction in neutralizing antibodies and VE against infection, but more preserved protection against severe disease – highlights the multifaceted nature of vaccine-induced immunity. While neutralizing antibodies are critical for blocking initial infection (sterilizing immunity), other immune components, including non-neutralizing antibodies mediating functions like antibody-dependent cellular cytotoxicity (ADCC) and, crucially, T-cell responses, likely contribute significantly to controlling viral replication and preventing progression to severe disease once infection occurs (McMahan et al., 2021; Keeton et al., 2022). The relative conservation of T-cell epitopes across variants provides a biological basis for this sustained protection against severe outcomes.

Booster vaccinations have proven essential for maintaining and broadening immunity against variants. They effectively increase antibody concentrations, overcoming, to some extent, the reduced binding affinity to variant spike proteins (Garcia-Beltran et al., 2022). The development and deployment of bivalent boosters underscore the key strength of mRNA technology: its adaptability. The platform allows for relatively rapid modification of the vaccine antigen sequence to match circulating strains, aiming to improve the specificity and breadth of the immune response (Chalkias et al., 2022). While the incremental benefit of bivalent over monovalent boosters against severe disease is still debated in some contexts, their superior neutralization profiles against contemporary variants are generally accepted (Davis-Gardner et al., 2023; Link-Gelles et al., 2023).

Compared to some other vaccine platforms, mRNA technology offers distinct advantages in speed of adaptation. While viral vector and inactivated virus vaccines also faced challenges with variants, updating them can sometimes be a more complex and potentially slower process. However, all platforms have generally shown better preservation of protection against severe disease than against infection across different variants.

Despite its successes, the mRNA platform is not without limitations. These include the observed waning of neutralizing antibody titers over months, necessitating booster doses; logistical challenges associated with ultra-cold chain requirements for some formulations (though improving); and observed reactogenicity (temporary side effects like fever and fatigue). While safety monitoring has been extensive and reassuring regarding rare adverse events like myocarditis, long-term impacts remain under surveillance (Bozkurt et al., 2021).

This review is subject to limitations inherent in any literature synthesis. The rapid pace of research means some findings, particularly regarding the newest subvariants, may be preliminary (often from preprints). Heterogeneity in study methodologies, populations, and definitions makes direct comparison of VE estimates challenging. Potential publication bias favouring significant findings may also exist.

The implications for public health are clear. Ongoing genomic surveillance is mandatory to track viral evolution and identify emerging variants promptly. Vaccination strategies need to remain flexible, incorporating regular reviews of the need for, timing of, and composition of booster doses, potentially tailored to high-risk populations. Research into correlates of protection beyond neutralizing antibodies, particularly the role and durability of T-cell responses and mucosal immunity, is crucial for guiding next-generation vaccine design. Efforts towards developing pan-coronavirus vaccines, aiming to elicit broader protection against future variants and potentially other coronaviruses, represent a key future direction (Morens et al., 2022).

---

**7. Conclusion**

mRNA vaccine technology has been instrumental in combating the COVID-19 pandemic, demonstrating remarkable initial efficacy and saving countless lives. While the emergence of SARS-CoV-2 variants, particularly Omicron and its sublineages, has led to significant immune escape and reduced effectiveness against infection, protection against severe disease, hospitalization, and death has remained more durable, especially following booster vaccination. This resilient protection highlights the importance of cellular immunity induced by these vaccines.

The inherent flexibility and speed of the mRNA platform have enabled rapid adaptation, leading to the development of variant-updated boosters that help restore and broaden immune responses. However, viral evolution is an ongoing process. Continued global surveillance, strategic deployment of primary and booster vaccination, and sustained investment in research are imperative. This includes refining our understanding of correlates of protection, optimizing booster composition and timing, and pursuing next-generation vaccines with greater breadth and durability to enhance preparedness against current and future viral threats. The experience with SARS-CoV-2 has unequivocally validated mRNA technology as a cornerstone of modern vaccinology and pandemic response.

---

**8. References (Illustrative Examples in APA 7th Edition Format)**

Accorsi, P. A., Britton, A., Fleming-Dutra, K. E., Zhu, W., Lin, Y., ... & Gaglani, M. (2022). Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. *JAMA*, *327*(7), 639–651. https://doi.org/10.1001/jama.2022.0470

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., ... & Ramsay, M. E. (2022). Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. *New England Journal of Medicine*, *386*(16), 1532–1546. https://doi.org/10.1056/NEJMoa2119451

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., ... & Zaks, T. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *New England Journal of Medicine*, *384*(5), 403–416. https://doi.org/10.1056/NEJMoa2035389

Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis with COVID-19 mRNA vaccines. *Circulation*, *144*(6), 471–484. https://doi.org/10.1161/CIRCULATIONAHA.121.056135

Cao, Y., Jian, F., Wang, J., Yu, Y., Song, W., ... & Xie, X. S. (2022). Imprinted SARS-CoV-2 humoral immunity induces broad Omicron neutralization. *Nature*, *614*(7948), 521–529. https://doi.org/10.1038/s41586-022-05644-7 [Note: Example of preprint conversion or newer study]

Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., ... & Sigal, A. (2021). Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. *Nature*, *602*(7898), 654–656. https://doi.org/10.1038/s41586-021-04387-1

Chalkias, S., Harper, C., Vrbicky, K., Walsh, S. R., Essink, B., ... & Girard, B. (2022). A bivalent Omicron-containing booster vaccine against Covid-19. *New England Journal of Medicine*, *387*(14), 1279–1291. https://doi.org/10.1056/NEJMoa2208343

Davis-Gardner, M. E., Lai, L., Bian, L., Lee, C., Wen, J., ... & Montefiori, D. C. (2023). Neutralization against BA.2.86 after bivalent or monovalent boosting. *New England Journal of Medicine*, *389*(20), 1922-1924. https://doi.org/10.1056/NEJMc2311117 [Illustrative newer citation]

Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., ... & Balazs, A. B. (2022). mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell*, *185*(3), 457–466.e4. https://doi.org/10.1016/j.cell.2021.12.033

Gao, Y., Cai, C., Grifoni, A., Müller, T. R., Ni, T., ... & Peters, B. (2022). Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. *Nature Medicine*, *28*(3), 472–476. https://doi.org/10.1038/s41591-022-01700-x

Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., ... & Robertson, D. L. (2021). SARS-CoV-2 variants, spike mutations and immune escape. *Nature Reviews Microbiology*, *19*(7), 409–424. https://doi.org/10.1038/s41579-021-00573-0

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., ... & Beigel, J. H. (2020). An mRNA vaccine against SARS-CoV-2 — Preliminary Report. *New England Journal of Medicine*, *383*(20), 1920–1931. https://doi.org/10.1056/NEJMoa2022483

Keeton, R., Tincho, M. B., Pisculli, M., Mennen, M., Richardson, S. I., ... & Gray, G. (2022). T cell responses to SARS-CoV-2 spike cross-recognize Omicron. *Nature*, *603*(7901), 488–492. https://doi.org/10.1038/s41586-022-04460-3

Krammer, F. (2020). SARS-CoV-2 vaccines in development. *Nature*, *586*(7830), 516–527. https://doi.org/10.1038/s41586-020-2798-3

Lauring, A. S., & Hodcroft, E. B. (2021). Genetic variants of SARS-CoV-2—what do they mean? *JAMA*, *325*(6), 529–531. https://doi.org/10.1001/jama.2020.27124

Link-Gelles, R., Ciesla, A. A., Mak, J., Miller, J. D., Valdez, B. A., ... & Britton, A. (2023). Early estimates of bivalent mRNA vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5– and XBB/XBB.1.5–related sublineages among immunocompetent adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023. *MMWR. Morbidity and Mortality Weekly Report*, *72*(5), 119–124. http://dx.doi.org/10.15585/mmwr.mm7205e1

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., ... & Ramsay, M. (2021). Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. *New England Journal of Medicine*, *385*(7), 585–594. https://doi.org/10.1056/NEJMoa2108891

McMahan, K., Yu, J., Mercado, N. B., Loos, C., Tostanoski, L. H., ... & Barouch, D. H. (2021). Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*, *590*(7847), 630–634. https://doi.org/10.1038/s41586-020-03041-6

Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2022). Universal coronavirus vaccines — An urgent need. *New England Journal of Medicine*, *386*(4), 297–299. https://doi.org/10.1056/NEJMp2118468

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., ... & Corbett, K. S. (2022). SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. *New England Journal of Medicine*, *386*(11), 1088–1091. https://doi.org/10.1056/NEJMc2119912

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. *Nature Reviews Drug Discovery*, *17*(4), 261–279. https://doi.org/10.1038/nrd.2017.243

Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., ... & Schwartz, O. (2022). Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature*, *602*(7898), 671–675. https://doi.org/10.1038/s41586-021-04389-z

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., ... & Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England Journal of Medicine*, *383*(27), 2603–2615. https://doi.org/10.1056/NEJMoa2034577

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., ... & Türeci, Ö. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature*, *586*(7830), 594–599. https://doi.org/10.1038/s41586-020-2814-7

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021). SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet*, *397*(10293), 2461–2462. https://doi.org/10.1016/S0140-6736(21)01358-1

Tarke, A., Coelho, C. H., Zhang, Z., Dan, J. M., Yu, E. D., ... & Sette, A. (2022). SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. *Cell*, *185*(5), 847–859.e11. https://doi.org/10.1016/j.cell.2022.01.015

Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., ... & Tartof, S. Y. (2022). Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. *Nature Medicine*, *28*(5), 1063–1071. https://doi.org/10.1038/s41591-022-01753-y

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., ... & Ho, D. D. (2021). Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature*, *593*(7857), 130–135. https://doi.org/10.1038/s41586-021-03398-2

Wang, Q., Guo, Y., Iketani, S., Nair, M. S., Li, Z., ... & Ho, D. D. (2022). Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. *Nature*, *608*(7923), 603–608. https://doi.org/10.1038/s41586-022-05053-w

---